Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κb activation and NFATc1 induction

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7460-7466

  Kim, Kabsun ^a   Kim, Jung Ha ^a   Youn, Bang Ung ^a   Jin, Hye Mi ^a   Kim, Nacksung ^a  

^a National Research Laboratory for Regulation of Bone Metabolism and Disease   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE PIM 1; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; ENZYME ACTIVATION; GENE SILENCING; GENETIC TRANSDUCTION; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; MACROPHAGES; MAP KINASE KINASE KINASES; MICE; MICE, INBRED ICR; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-PIM-1; RANK LIGAND; RNA INTERFERENCE; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 78650644892     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000885     Document Type: Article

References (34)

1. Boyle, W. J., W. S. Simonet, and D. L. Lacey. 2003. Osteoclast differentiation and activation. Nature 423:337-342.
2. Walsh, M. C., N. Kim, Y. Kadono, J. Rho, S. Y. Lee, J. Lorenzo, and Y. Choi. 2006. Osteoimmunology: interplay between the immune system and bone metabolism. Annu. Rev. Immunol. 24:33-63.
3. Kim, N., Y. Kadono, M. Takami, J. Lee, S. H. Lee, F. Okada, J. H. Kim, T. Kobayashi, P. R. Odgren, H. Nakano, et al. 2005. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202:589-595.
4. Lee, Z. H., and H. H. Kim. 2003. Signal transduction by receptor activator of nuclear factor kB in osteoclasts. Biochem. Biophys. Res. Commun. 305:211-214.
5. Mizukami, J., G. Takaesu, H. Akatsuka, H. Sakurai, J. Ninomiya-Tsuji, K. Matsumoto, and N. Sakurai. 2002. Receptor activator of NF-kB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 22:992-1000.
6. Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inoue, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-IkB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252-256.
7. Asagiri, M., and H. Takayanagi. 2007. The molecular understanding of osteoclast differentiation. Bone 40:251-264.
8. Breuer, M. L., H. T. Cuypers, and A. Berns. 1989. Evidence for the involvement of Pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J. 8:743-748.
9. Fox, C. J., P. S. Hammerman, and C. B. Thompson. 2005. The Pim kinases control rapamycin-resistant T cell survival and activation. J. Exp. Med. 201:259-266.
10. Bachmann, M., and T. Möröy. 2005. The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol. 37:726-730.
11. Mikkers, H., M. Nawijn, J. Allen, C. Brouwers, E. Verhoeven, J. Jonkers, and A. Berns. 2004. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol. Cell. Biol. 24:6104-6115.
12. Chen, X. P., J. A. Losman, S. Cowan, E. Donahue, S. Fay, B. Q. Vuong, M. C. Nawijn, D. Capece, V. L. Cohan, and P. Rothman. 2002. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc. Natl. Acad. Sci. USA 99:2175-2180.
13. Mochizuki, T., C. Kitanaka, K. Noguchi, T. Muramatsu, A. Asai, and Y. Kuchino. 1999. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase: implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J. Biol. Chem. 274:18659-18666.
14. Rainio, E. M., J. Sandholm, and P. J. Koskinen. 2002. Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J. Immunol. 168:1524-1527.
15. Yan, B., M. Zemskova, S. Holder, V. Chin, A. Kraft, P. J. Koskinen, and M. Lilly. 2003. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BADinduced cell death. J. Biol. Chem. 278:45358-45367.
16. Lilly, M., J. Sandholm, J. J. Cooper, P. J. Koskinen, and A. Kraft. 1999. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 18:4022-4031.
17. Deneen, B., S. M. Welford, T. Ho, F. Hernandez, I. Kurland, and C. T. Denny. 2003. PIM3 proto-oncogene kinase is a common transcriptional target of divergent EWS/ETS oncoproteins. Mol. Cell. Biol. 23:3897-3908.
18. Lee, N. K., H. K. Choi, D. K. Kim, and S. Y. Lee. 2006. Rac1 GTPase regulates osteoclast differentiation through TRANCE-induced NF-kB activation. Mol. Cell. Biochem. 281:55-61.
19. Kim, K., J. H. Kim, J. Lee, H. M. Jin, H. Kook, K. K. Kim, S. Y. Lee, and N. Kim. 2007. MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood 109:3253-3259.
20. Kim, K., J. H. Kim, J. Lee, H. M. Jin, S. H. Lee, D. E. Fisher, H. Kook, K. K. Kim, Y. Choi, and N. Kim. 2005. Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis. J. Biol. Chem. 280:35209-35216.
21. Kim, N., M. Takami, J. Rho, R. Josien, and Y. Choi. 2002. A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J. Exp. Med. 195:201-209.
22. Kim, J. H., H. M. Jin, K. Kim, I. Song, B. U. Youn, K. Matsuo, and N. Kim. 2009. The mechanism of osteoclast differentiation induced by IL-1. J. Immunol. 183:1862-1870.
23. Kim, J. H., K. Kim, H. M. Jin, I. Song, B. U. Youn, J. Lee, and N. Kim. 2009. Silibinin inhibits osteoclast differentiation mediated by TNF family members. Mol. Cells 28:201-207.
24. Takaesu, G., R. M. Surabhi, K. J. Park, J. Ninomiya-Tsuji, K. Matsumoto, and R. B. Gaynor. 2003. TAK1 is critical for IkB kinase-mediated activation of the NF-kB pathway. J. Mol. Biol. 326:105-115.
25. Kim, J. H., K. Kim, H. M. Jin, B. U. Youn, I. Song, H. S. Choi, and N. Kim. 2008. Upstream stimulatory factors regulate OSCAR gene expression in RANKL-mediated osteoclast differentiation. J. Mol. Biol. 383:502-511.
26. Kim, K., J. Lee, J. H. Kim, H. M. Jin, B. Zhou, S. Y. Lee, and N. Kim. 2007. Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by downregulation of NFATc1 and osteoclast-associated receptor. J. Immunol. 178:5588-5594.
27. Lee, J., K. Kim, J. H. Kim, H. M. Jin, H. K. Choi, S. H. Lee, H. Kook, K. K. Kim, Y. Yokota, S. Y. Lee, et al. 2006. Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood 107:2686-2693.
28. Saris, C. J., J. Domen, and A. Berns. 1991. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 10:655-664.
29. Allen, J. D., E. Verhoeven, J. Domen, M. van der Valk, and A. Berns. 1997. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 15:1133-1141.
30. Feldman, J. D., L. Vician, M. Crispino, G. Tocco, V. L. Marcheselli, N. G. Bazan, M. Baudry, and H. R. Herschman. 1998. KID-1, a protein kinase induced by depolarization in brain. J. Biol. Chem. 273:16535-16543.
31. Zemskova, M., E. Sahakian, S. Bashkirova, and M. Lilly. 2008. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 283:20635-20644.
32. Huang, H., J. Ryu, J. Ha, E. J. Chang, H. J. Kim, H. M. Kim, T. Kitamura, Z. H. Lee, and H. H. Kim. 2006. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kB transactivation by RANKL. Cell Death Differ. 13:1879-1891.
33. Takatsuna, H., M. Asagiri, T. Kubota, K. Oka, T. Osada, C. Sugiyama, H. Saito, K. Aoki, K. Ohya, H. Takayanagi, and K. Umezawa. 2005. Inhibition of RANKL-induced osteoclastogenesis by (2)-DHMEQ, a novel NF-kB inhibitor, through downregulation of NFATc 1. J. Bone Miner. Res. 20:653-662.
34. Asagiri, M., K. Sato, T. Usami, S. Ochi, H. Nishina, H. Yoshida, I. Morita, E. F. Wagner, T. W. Mak, E. Serfling, and H. Takayanagi. 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202:1261-1269.